| Date Filed | Type | Description |
| 08/22/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 08/21/2023 |
8-K
| Appointed a new director|
Docs:
|
"NON QUALIFIED STOCK OPTION AGREEMENT NON QUALIFIED STOCK OPTION AGREEMENT made this 17 th day of August, 2023 between PSYCHEMEDICS CORPORATION, a Delaware corporation , and Brian Hullinger, an employee or independent contractor of the Corporation or one or more of its subsidiaries . The Corporation desires, by affording the Optionee an opportunity to purchase shares of its Common Stock, $.005 par value , as hereinafter provided, and as an inducement material to the Optionee’ s entering into employment as Chief Executive Officer of the Corporation, in accordance with the terms of the Offer of Employment between Optionee and the Corporation dated July 12, 2023 NOW, THEREFORE, in consideration of the mutual covenants hereinafter set forth and for other good and valuable consideration, the par...",
"NON QUALIFIED STOCK OPTION AGREEMENT",
"Psychemedics Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635 ACTON, Mass., Aug. 18, 2023 -- Psychemedics Corporation , the world’s largest provider of hair testing for drugs of abuse, announced the grant of inducement awards to its newly appointed President and Chief Executive Officer, Brian Hullinger, upon his entering into employment with the Company in accordance with Nasdaq Listing Rule 5635. Mr. Hullinger received an inducement grant option to purchase up to 300,000 shares of common stock. The inducement awards were granted on August 17, 2023, Mr. Hullinger’s hire date as the Chief Executive Officer, and also the date on which he was elected to the Psychemedics Corporation Board of Directors. The options have a ten-year term and an exercise price of $4.65 per shar..." |
|
| 08/17/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 08/14/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/11/2023 |
8-K
| Quarterly results |
| 07/21/2023 |
8-K
| Quarterly results |
| 07/21/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 07/21/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 07/14/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 05/11/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/09/2023 |
8-K
| Quarterly results |
| 03/27/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/21/2023 |
8-K
| Quarterly results |
| 02/14/2023 |
SC 13G/A
| KUBACKI RAYMOND C JR reports a 6.5% stake in Psychemedics Corporation |
| 02/13/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 12/30/2022 |
8-K
| Quarterly results |
| 11/10/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 11/09/2022 |
8-K
| Quarterly results |
| 08/17/2022 |
8-K
| Quarterly results |
| 08/10/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 08/09/2022 |
8-K
| Quarterly results |
| 07/25/2022 |
8-K
| Quarterly results |
| 07/06/2022 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 06/10/2022 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 06/09/2022 |
8-K
| Quarterly results |
| 05/11/2022 |
10-Q
| Quarterly Report for the period ended March 31, 2022 |
| 05/10/2022 |
8-K
| Quarterly results |
| 05/10/2022 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 04/21/2022 |
SC 13D/A
| Kamin Peter reports a 11.2% stake in Psychemedics Corp |
| 03/30/2022 |
10-K
| Annual Report for the period ended December 31, 2021 |
| 03/29/2022 |
8-K
| Quarterly results |
| 03/22/2022 |
8-K
| Investor presentation|
Docs:
|
"Psychemedics Corporation Welcomes Drew Reynolds to Its Board of Directors and Announces the Retirement of Harry Connick From His Director Role ACTON, Mass., March 22, 2022 -- Psychemedics Corporation , the world’s largest provider of hair testing for drugs of abuse, is pleased to welcome Andrew “Drew” M. Reynolds to the Psychemedics Board of Directors effective April 4th , 2022. Mr. Reynolds will also serve as a member of the Audit, Compensation, and Nominating and Governance Committees. Mr. Reynolds currently serves as a board director and independent consultant to a number of companies. He has over 25 years-experience and has held positions in strategy, corporate development, sales and marketing, both domestically and internationally. He has a strong track record of driving profitable gr..." |
|
| 03/10/2022 |
8-K
| Quarterly results |
| 02/14/2022 |
SC 13G/A
| KUBACKI RAYMOND C JR reports a 6% stake in Psychemedics Corporation. |
|